Cartesian Therapeutics (RNAC) Net Cash Flow (2015 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly Net Cash Flow of -$6.5 million for Q1 2026, up 79.85% year-over-year from -$3.6 million in Q1 2025, and up 64.44% quarter-over-quarter from -$18.3 million in Q4 2025.
Cartesian Therapeutics (RNAC) Net Cash Flow (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Net Cash Flow for 12 consecutive years, with -$6.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 79.85% year-over-year to -$6.5 million; the TTM figure through Mar 2026 stood at -$61.7 million (down 179.87% YoY), while the FY2025 annual figure was -$87.4 million, down 164.3% from the prior year.
- Net Cash Flow grew to -$6.5 million in Q1 2026 per RNAC's latest filing, from -$18.3 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $132.0 million in Q3 2024 and bottomed at -$34.0 million in Q3 2023.
- Historically, Net Cash Flow has averaged $291529.4 across 5 years, with a median of -$6.6 million in 2024.
- On a YoY basis, Net Cash Flow climbed as much as 7416.87% in 2022 and fell as far as 992.78% in 2022.
- Cartesian Therapeutics' Net Cash Flow stood at -$6.4 million in 2022, then surged by 57.42% to -$2.7 million in 2023, then plunged by 142.73% to -$6.6 million in 2024, then sank by 177.74% to -$18.3 million in 2025, then jumped by 64.44% to -$6.5 million in 2026.
- Business Quant data shows RNAC's Net Cash Flow at -$6.5 million in Q1 2026, -$18.3 million in Q4 2025, and -$16.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Cartesian Therapeutics | 265.54 Mn | 265.54 Mn | - | 28.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.99 Mn |
| Jun 30, 2026 | 28.99 Mn |
| Mar 31, 2026 | -6.49 Mn |
| Mar 31, 2026 | -6.49 Mn |
| Dec 31, 2025 | -18.26 Mn |
| Dec 31, 2025 | -18.26 Mn |
| Sep 30, 2025 | -16.93 Mn |
| Sep 30, 2025 | -16.93 Mn |
| Jun 30, 2025 | -20.06 Mn |
| Jun 30, 2025 | -20.06 Mn |
| Mar 31, 2025 | -32.21 Mn |
| Mar 31, 2025 | -32.21 Mn |
| Dec 31, 2024 | -6.57 Mn |
| Dec 31, 2024 | -6.57 Mn |
| Sep 30, 2024 | 131.99 Mn |
| Sep 30, 2024 | 131.99 Mn |
| Jun 30, 2024 | -15.91 Mn |
| Jun 30, 2024 | -15.91 Mn |
| Mar 31, 2024 | 26.51 Mn |
| Mar 31, 2024 | 26.51 Mn |